Pulse Explorar nav.journalClub Debates Tendências Pesquisadores Revistas

Início Explorar nav.journalClub Tendências

⌘+K

March 28, 2026JAIDS Journal of Acquired Immune Deficiency Syndromes2 citationsOpen Access

Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People with HIV at 48 Weeks

View Full Paper

LVLaurie A. VanderVeen LSLisa SelzerGilead Sciences (United States)SCSilvia Chang

Key Points

The study aims to analyze the resistance profile of islatravir plus lenacapavir in people with HIV at 48 weeks.
Participants received once-weekly oral islatravir plus lenacapavir treatment.
Resistance analysis was conducted after 48 weeks.
Monitoring included participants with pre-existing mutations.
High rates of viral suppression were maintained in all participants.
No participants developed drug resistance during the study period.

Abstract

ISL+LEN maintained high rates of VS, including in one participant with pre-existing M184V. No participants developed drug resistance. These findings support the ongoing evaluation of QW oral ISL+LEN for HIV-1 treatment.

Perguntar à IA

Like

Bookmark

Share

View Full Paper

Perguntar à IA

Like

Bookmark

Share

View Full Paper

Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People with HIV at 48 Weeks | Synapse

Cite This Study

VanderVeen et al. (Thu,) studied this question.

synapsesocial.com/papers/69c771198bbfbc51511e0f00 https://doi.org/https://doi.org/10.1097/qai.0000000000003873